Thorac Surg 2013;96(4):1413–1419 395 Backer CL, Deal BJ, Mavroudis C, Franklin WH, Stewart RD Conversion of the failed Fontan circulation Cardiol Young 2006;16(suppl 1):85–91 396 Tsao S, Deal BJ, Backer CL, et al Device management of arrhythmias after Fontan conversion J Thorac Cardiovasc Surg 2009;138(4):937–940 397 Backer CL Rescuing the failing Fontan Heart 2016;102(14):1077–1078 398 Poh CL, Cochrane A, Galati JC, et al Ten-year outcomes of Fontan conversion in Australia and New Zealand demonstrate the superiority of a strategy of early conversion Eur J Cardiothorac Surg 2016;49(2):530–535 [discussion 5] 399 Davies RR, Russo MJ, Yang J, et al Listing and transplanting adults with congenital heart disease Circulation 2011;123(7):759–767 400 Lund LH, Edwards LB, Dipchand AI, et al The registry of the International Society for Heart and Lung Transplantation: thirty-third adult heart transplantation Report-2016; focus theme: primary diagnostic indications for transplant J Heart Lung Transplant 2016;35(10):1158–1169 401 Beal EW, Mumtaz K, Hayes D Jr, Whitson BA, Black SM Combined heart-liver transplantation: indications, outcomes and current experience Transplant Rev (Orlando) 2016;30(4):261–268 402 Te HS, Anderson AS, Millis JM, Jeevanandam V, Jensen DM Current state of combined heartliver transplantation in the United States J Heart Lung Transplant 2008;27(7):753–759 403 Kiesewetter CH, Sheron N, Vettukattill JJ, et al Hepatic changes in the failing Fontan circulation Heart 2007;93(5):579–584 404 Wu FM, Ukomadu C, Odze RD, et al Liver disease in the patient with Fontan circulation Congenit Heart Dis 2011;6(3):190–201 405 Ohuchi H, Negishi J, Hayama Y, et al Renal resistive index reflects Fontan pathophysiology and predicts mortality Heart 2017;103(20):1631–1637 406 Elder RW, McCabe NM, Veledar E, et al Risk factors for major adverse events late after Fontan palliation Congenit Heart Dis 2015;10:159– 168 407 Goldberg DJ, Paridon SM Fontan circulation: the search for targeted therapy Circulation 2014;130(23):1999–2001 408 Oldenburger NJ, Mank A, Etnel J, Takkenberg JJ, Helbing WA Drug therapy in the prevention of failure of the Fontan circulation: a systematic review Cardiol Young 2016;26(5):842–850 409 Hedlund ER, Lundell B, Villard L, Sjoberg G Reduced physical exercise and health-related quality of life after Fontan palliation Acta Paediatr 2016;105(11):1322–1328 410 Berghammer M Is being physically active the key to a good quality of life for patients living with Fontan circulation? Acta Paediatr 2016;105(11):1257–1258 411 Ait Ali L, Pingitore A, Piaggi P, et al Respiratory training late after Fontan intervention: impact on cardiorespiratory performance Pediatr Cardiol 2018 [Epub ahead of print] 412 Loomba RS Angiotensin converting enzyme inhibition in those with functionally univentricular hearts: is there a problem with overuse? SM J Pediatr 2017;2(1):1006–1008 413 Oemrawsingh RM, Akkerhuis KM, Van Vark LC, et al Individualized angiotensin-converting enzyme (ACE)-inhibitor therapy in stable coronary artery disease based on clinical and pharmacogenetic determinants: the PERindopril GENEtic (PERGENE) Risk Model J Am Heart Assoc 2016;5(3):e002688 414 d'Udekem Y, Rychik J Towards the goal of achieving a normal duration and quality of life after Fontan operation: creation of the